Poolbeg Pharma PLC (POLBF) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $73.1M is the value of all shares combined. Beta 1.82: the stock has moved about 82% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerPoolbeg Pharma PLC (POLBF) trades at $0.0958. Poolbeg Pharma PLC is a clinical-stage pharmaceutical company focused on developing innovative treatments for infectious diseases. Market cap: $73.1M, Sector: Healthcare.
Price as of · Last analyzed: Jun 14, 2026Analyst Coverage for POLBF: POLBF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
Thousands of the 20,000+ US stocks here carry a MoonshotScore.
Scored companies in the same industry:
Poolbeg Pharma PLC (POLBF) Healthcare & Pipeline Overview
Poolbeg Pharma PLC is a clinical-stage biotech firm specializing in the development of innovative therapies for infectious diseases, leveraging advanced technologies and a promising product pipeline to address critical health challenges.
What Is the Investment Thesis for POLBF?
The company's lead candidates, POLB 001 and POLB 002, are positioned to address significant market needs, particularly in the wake of global health challenges. The global influenza treatment market is projected to grow significantly, providing a robust opportunity for POLB 001, while the RNA-based immunotherapy market is expected to expand rapidly, enhancing the potential for POLB 002. Additionally, the company's access to advanced micro- and nanoencapsulation technology offers a competitive advantage in developing oral vaccine delivery systems. Poolbeg Pharma's commitment to leveraging artificial intelligence in drug discovery further enhances its value proposition, potentially leading to accelerated development timelines and reduced costs. However, investors should be aware of the inherent risks associated with clinical-stage biotech firms, including regulatory hurdles and market competition.
Based on FMP financials and quantitative analysis
POLBF Key Highlights
Market capitalization of $73.1M reflects the company's emerging status in the biotechnology sector.
- Beta of 1.82 indicates higher volatility compared to the overall market, characteristic of clinical-stage biotech firms.
- No dividend yield as the company reinvests in R&D for product pipeline advancement.
- Focus on infectious diseases positions Poolbeg Pharma in a critical and growing healthcare market.
- Innovative use of AI in drug discovery could lead to faster and more efficient development processes.
Who Are POLBF's Competitors?
POLBF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| MRNA Moderna, Inc. | $199.33 | +1.29% | $80.7B | 31 5-pillar |
| NVAX Novavax, Inc. | $7.72 | -3.02% | $1.27B | — |
| BNTX BioNTech SE | $83.26 | -1.89% | $20.6B | 32 5-pillar |
| RLYB Rallybio Corporation | $15.26 | -0.20% | $85.5M | 82 5-pillar |
| ICCC ImmuCell Corporation | $11.25 | -0.71% | $102M | 82 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $3.89 | +0.52% | $169M | 72 5-pillar |
| CGEN Compugen Ltd. | $1.88 | -4.08% | $178M | 69 5-pillar |
| PLX Protalix BioTherapeutics, Inc. | $3.06 | +1.32% | $258M | 90 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are POLBF's Key Strengths?
Innovative product pipeline targeting critical infectious diseases.
- Access to advanced technologies for drug delivery and discovery.
- Strong leadership with expertise in pharmaceutical development.
What Are POLBF's Weaknesses?
Limited operational history as a newly established company.
- Small employee base may limit scalability in development efforts.
- No revenue generation yet as products are still in development.
What Could Drive POLBF Stock Higher?
Clinical trial results for POLB 001 expected in Q4 2026.
- Development of POLB 002 with anticipated regulatory submissions in 2027.
- Expansion of the oral vaccine delivery platform technology in 2026.
- Collaboration with research institutions to enhance drug discovery capabilities.
- Presentation of data at industry conferences to attract potential partnerships.
What Are the Key Risks for POLBF?
Negative return on equity (-71.3%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles and approval processes for clinical-stage products.
- Market competition from established pharmaceutical companies.
- Dependency on successful clinical trial outcomes for product viability.
- Economic downturns affecting funding and investment opportunities.
What Are the Growth Opportunities for POLBF?
- Growth opportunity 1: The global influenza treatment market is projected to reach $10 billion by 2028, driven by rising incidences of influenza and the need for effective therapies. Poolbeg Pharma's POLB 001 stands to capture significant market share as a novel p38 MAP Kinase inhibitor, particularly in the wake of increased public health awareness following pandemics.
- Growth opportunity 2: The RNA-based immunotherapy market is expected to grow exponentially, with a projected CAGR of 25% through 2027. Poolbeg Pharma's POLB 002, as a first-in-class intranasal immunotherapy, is well-positioned to capitalize on this trend by addressing respiratory viral infections, a key area of unmet need.
- Growth opportunity 3: The oral vaccine delivery platform utilizing micro- and nanoencapsulation technology has the potential to revolutionize vaccine administration. With a growing emphasis on patient compliance and ease of administration, this technology could tap into a market projected to exceed $5 billion by 2026.
- Poolbeg Pharma's POLB 003 aims to prevent Melioidosis, targeting a niche yet critical area within the vaccine landscape, potentially leading to substantial market penetration.
- Growth opportunity 5: The integration of artificial intelligence in drug discovery is transforming the pharmaceutical landscape. Poolbeg Pharma's commitment to leveraging AI could lead to faster identification of viable drug candidates, reducing time to market and development costs, thus enhancing overall operational efficiency.
What Opportunities Does POLBF Have?
- Growing global demand for effective treatments for infectious diseases.
- Potential for strategic partnerships to enhance market reach.
- Expansion into emerging markets with unmet healthcare needs.
What Are POLBF's Competitive Advantages?
- Access to proprietary micro- and nanoencapsulation technology enhances product delivery.
- Strong focus on unmet medical needs in infectious diseases provides a competitive edge.
- Innovative use of artificial intelligence in drug discovery streamlines development.
- Diverse product pipeline reduces dependency on any single product's success.
- Strategic partnerships can enhance market access and resource sharing.
What Does POLBF Do?
Founded in 2021 and headquartered in London, United Kingdom, Poolbeg Pharma PLC operates as a clinical-stage pharmaceutical company dedicated to the development of treatments for infectious diseases. The company's innovative approach is exemplified by its diverse product pipeline, which includes POLB 001, a p38 MAP Kinase inhibitor aimed at treating severe influenza, and POLB 002, a first-in-class RNA-based immunotherapy designed for intranasal administration to combat respiratory viral infections. Additionally, Poolbeg Pharma is advancing POLB 003, an intramuscular vaccine targeting Melioidosis, a serious bacterial infection. Beyond these specific drug candidates, the company has secured licensed access to advanced micro- and nanoencapsulation technology, which is being utilized to create an oral vaccine delivery platform that effectively transports immune-stimulating antigens to targeted areas of the gut. Poolbeg Pharma also employs an artificial intelligence-powered program to enhance drug discovery processes and is developing a biomarker platform to identify individuals at risk of progressing to severe disease. The company’s sophisticated, model-derived vaccine discovery platform aims to uncover novel vaccine candidates, positioning Poolbeg Pharma as a forward-thinking player in the biotechnology sector.
What Products and Services Does POLBF Offer?
- Develops innovative treatments for infectious diseases.
- Focuses on clinical-stage pharmaceutical development.
- Holds a diverse product pipeline including vaccines and immunotherapies.
- Utilizes advanced micro- and nanoencapsulation technology for vaccine delivery.
- Employs artificial intelligence to enhance drug discovery processes.
- Aims to identify at-risk individuals through biomarker development.
How Does POLBF Make Money?
- Generates revenue through the development and licensing of pharmaceutical products.
- Focuses on clinical trials to validate product efficacy and safety.
- Explores partnerships and collaborations for technology access and market reach.
- Plans to monetize successful products through sales and licensing agreements.
- Invests in R&D to expand its product pipeline and technological capabilities.
What Industry Does POLBF Operate In?
The biotechnology industry is experiencing rapid growth, driven by advancements in technology and increasing demand for innovative healthcare solutions. The global market for infectious disease therapeutics is expanding, with a projected CAGR of over 8% through the next five years. Poolbeg Pharma PLC is strategically positioned within this landscape, focusing on unmet medical needs in infectious diseases, particularly in the context of recent global health crises. The competitive landscape includes established pharmaceutical companies and emerging biotech firms, making innovation and speed to market critical for success.
Who Are POLBF's Key Customers?
- Healthcare providers looking for innovative treatment options.
- Pharmaceutical companies seeking licensing agreements for new therapies.
- Government health agencies focused on infectious disease prevention.
- Research institutions interested in collaboration for drug development.
- Patients requiring effective treatments for infectious diseases.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
Forward Outlook
Wall Street analysts project Poolbeg Pharma PLC revenue of about $0 for fiscal 2026, with EPS near $-0.01.
POLBF Valuation & Market Position
With a $73.1M market cap, Poolbeg Pharma PLC sits in the micro-cap segment of the market.
Key Financial Metrics
Return on equity for Poolbeg Pharma PLC stands at -71.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -76.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -10.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 12.44 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -12.9%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Poolbeg Pharma PLC's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 69.83 places it in the safe zone, indicating low near-term bankruptcy risk.
Earnings Track Record
Poolbeg Pharma PLC has missed Wall Street's EPS estimate in 0 of its last 4 reported quarters — a recurring pattern of falling short of estimates.
Company Profile
Poolbeg Pharma PLC operates in the Biotechnology industry within the Healthcare sector. It is headquartered in London, GB. The company is led by CEO Jeremy Skillington. POLBF has traded publicly since 2022.
POLBF Financials
Bull Case vs Bear Case
Bull Case
- Innovative product pipeline targeting critical infectious diseases.
- Access to advanced technologies for drug delivery and discovery.
- Strong leadership with expertise in pharmaceutical development.
- Upcoming: Clinical trial results for POLB 001 expected in Q4 2026.
Bear Case
- Limited operational history as a newly established company.
- Small employee base may limit scalability in development efforts.
- No revenue generation yet as products are still in development.
- Ongoing: Regulatory hurdles and approval processes for clinical-stage products.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · June 2026
POLBF Latest News
-
Gelion, Bango, Poolbeg Pharma, Georgina Energy, Kenmare Resources - Small Cap Snapshot
Yahoo! Finance: POLBF News · Oct 6, 2026
-
Poolbeg Pharma's Korean patent grant bolsters Cavendish's ‘buy' case
proactiveinvestors.com · Oct 6, 2026
-
Poolbeg Pharma retains ‘buy' rating at Cavendish after safety review allows trial to continue
proactiveinvestors.com · Sep 29, 2026
-
Poolbeg Pharma funded to finish both trials as it courts partners for cancer drug
proactiveinvestors.com · Sep 29, 2026
POLBF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for POLBF.
Price Targets
Wall Street price target analysis for POLBF.
POLBF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for POLBF; grades run from A+ (80-100) to F (below 30).
Latest News
Gelion, Bango, Poolbeg Pharma, Georgina Energy, Kenmare Resources - Small Cap Snapshot
Poolbeg Pharma's Korean patent grant bolsters Cavendish's ‘buy' case
Poolbeg Pharma retains ‘buy' rating at Cavendish after safety review allows trial to continue
Poolbeg Pharma funded to finish both trials as it courts partners for cancer drug
Leadership: Jeremy Skillington
CEO
Jeremy Skillington has extensive experience in the pharmaceutical and biotechnology sectors, having held various leadership roles in both public and private companies. He has a strong background in drug development and commercialization, with a focus on innovative therapies. Jeremy holds a PhD in Molecular Biology and has been instrumental in building teams and driving strategic initiatives in his previous roles.
Track Record: Under Jeremy's leadership, Poolbeg Pharma has successfully developed a robust pipeline of product candidates and secured licensing agreements for advanced technologies. His strategic vision has positioned the company to capitalize on emerging opportunities in the biotechnology sector.
POLBF OTC Market Information
The OTC Other tier represents stocks that are not listed on major exchanges like NYSE or NASDAQ, often including smaller or emerging companies. This tier typically has less stringent reporting requirements, which can lead to higher risk and lower liquidity compared to listed stocks.
- OTC Tier: OTC Other
- Lower visibility and recognition compared to companies listed on major exchanges.
- Potential for higher volatility due to limited trading volume.
- Regulatory risks associated with OTC stocks and compliance requirements.
- Review available financial statements and disclosures.
- Assess the company's product pipeline and clinical trial status.
- Investigate management's track record and industry experience.
- Evaluate the competitive landscape and market positioning.
- Monitor news and developments related to regulatory approvals.
- Incorporated in the UK with a focus on innovative healthcare solutions.
- Active engagement in clinical trials and product development.
- Partnerships with reputable organizations in the biotechnology sector.
What Investors Ask About Poolbeg Pharma PLC (POLBF) — Healthcare
Is POLBF a good stock to buy?
Stock Expert AI does not rate POLBF buy, sell or hold. Poolbeg Pharma PLC has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the POLBF stock price today?
The last price recorded on this page for Poolbeg Pharma PLC (POLBF) is $0.0958, as of the Nov 19, 2026 trading session. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
How does Poolbeg Pharma PLC navigate regulatory approval processes?
Poolbeg Pharma PLC is committed to adhering to regulatory standards set by agencies such as the FDA and EMA. The company engages in rigorous clinical trials to demonstrate the safety and efficacy of its products, ensuring compliance with regulatory requirements.
What are the key factors to evaluate for POLBF?
Evaluate POLBF on fundamentals, analyst consensus, and risk factors. No dividend yield as the company reinvests in R&D for product pipeline advancement. Not financial advice.
How frequently does POLBF data refresh on this page?
POLBF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven POLBF's recent stock price performance?
Poolbeg Pharma PLC (POLBF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product pipeline targeting critical infectious diseases. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider POLBF overvalued or undervalued right now?
Poolbeg Pharma PLC (POLBF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research POLBF before investing?
Before investing in Poolbeg Pharma PLC (POLBF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Data provided for informational purposes only.
- Data is based on the latest available information as of June 2026.